Bioheng Therapeutics is a clinical-stage company focused on allogeneic 'off-the-shelf' universal CAR-T therapies. The company aims to develop cell therapy platforms and products to address challenging unmet needs.

Bioheng Therapeutics

Bioheng Therapeutics | 173 followers on LinkedIn. We are committed to exploring the frontier of cell therapy, with a focus on allogeneic CAR-T | Bioheng Therapeutics is a clinical stage company focused on allogeneic / off-the-shelf CAR-T. Founded in 2017, we aim to develop the world&#39;s leading allogeneic cell therapy products to address some of the most challenging the unmet needs.

In March 2020, Bioheng received IND approval for CTA101, marking the first UCAR-T IND in China.

Pioneering allo CART, we are hiring in the US

Lu Han

Chief Technology Officer at Bioheng Therapeutics

Jenny Ni

Associate Director， Clinical Operation

Ming Gao

Regulatory affairs

Yanbo Liu

ASH2024 | Bioheng Therapeutics to Present Latest Clinical Data of RD13-02 for Treating R/R T-ALL/LBL Patients in Oral Presentation November 7, 2024, Bioheng Therapeutics (referred to as "Bioheng"), an innovative biopharmaceutical company dedicated to the development and commercialization of cell therapy products, announced today that it will present the latest Phase I clinical data of its universal CAR-T cell product RD13-02, targeting CD7 for the treatment of relapsed/refractory(R/R) T-ALL/LBL patients, in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting. The conference will take place from December 7-10, 2024, in San Diego, USA. Presentation title: A Novel Generation of Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed or Refractory CD7 Positive T-ALL/LBL: A Phase I Clinical Trial Abstract Number: 921 Presentation Time: Monday, December 9, 2024 at 3:15 p.m. Pacific Time Presentation location: San Diego Convention Center, Hall B About RD13-02 RD13-02 is a universal CAR-T cell product targeting CD7 derived from healthy donors, and intended for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). It is genetically modified to avoid fratricide, graft-versus-host disease (GvHD), and host-versus-graft rejection (HvG) while enhancing anti-tumor activity. RD13-02 can be prepared in a single batch for multiple people, achieving an "off-the-shelf" capability for patients in need of CAR-T cell therapy. For more details: https://lnkd.in/g2_7pp2D

EHA2024 | Bioheng Therapeutics Announces Latest Clinical Data of CD7-targeted Universal CAR-T Cell Product RD13-02 for Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma (R/R T-ALL/LBL) Patients, with an Impressive Response Rate of Up to 92% On June 16, 2024, Bioheng Therapeutics (referred to as "Bioheng"), an innovative biopharmaceutical company focusing on the development and commercialization of Universal Chimeric Antigen Receptor T-cell (UCAR-T) products, has presented the Phase I clinical data of its CD7-targeted Universal CAR-T cell product, RD13-02, for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL) patients at the 29th European Hematology Association (EHA 2024) Annual Congress, held in Madrid, Spain, from June 13 to 16, 2024, in the form of an academic poster. Abstract Title: Phase I Study of an Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed/Refractory CD7 Positive T-ALL/LBL Abstract Number: P1471 For more details: https://lnkd.in/geV2ZBpC

EHA2024 | Bioheng Therapeutics will Release The Latest Clinical Data of CD7-targeted Universal CAR-T Cell Product RD13-02 for Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma (R/R T-ALL/LBL) Patients On May 7th, 2024, Bioheng Therapeutics (referred to as "Bioheng"), an innovative biopharmaceutical company focusing on the development and commercialization of Universal Chimeric Antigen Receptor T-cell (UCAR-T) products, announced today that it will present the Phase I clinical data of its CD7-targeted Universal CAR-T cell product, RD13-02, for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL) patients at the 29th European Hematology Association (EHA 2024) Annual Congress, to be held in Madrid, Spain, from June 13 to 16, 2024, in the form of an academic poster. Abstract Title: Phase I Study of an Anti-CD7 Universal CAR-T Therapy for Patients with Relapsed/Refractory CD7 Positive T-ALL/LBL Abstract Number: P1471 Abstract release time: May 14, 2024, 16:00 (CEST) About RD13-02 RD13-02 is a universal CAR-T cell product targeting CD7 derived from healthy donors, and intended for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). It is genetically modified to avoid fratricide, graft-versus-host disease (GvHD), and host-versus-graft rejection (HvG) while enhancing anti-tumor activity. RD13-02 can be prepared in a single batch for multiple people, achieving an "off-the-shelf" capability for patients in need of CAR-T cell therapy.

Bioheng's CD7 UCAR-T and Allogeneic HSCT Sequential Therapy Study Published in the New England Journal of Medicine

We have updated our official website! 😉 Seeking more opportunities and collaborations: https://www.bioheng.com/

We're #hiring a new Head of Clinical Development in New Jersey. Apply today or share this post with your network.

BIOH

COM:BIOHENG

Bioheng Therapeutics

locale

market

industry

website

crunchbase

linkedin

investor of

Metrics